北京市金杜律师事务所 关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票的补充法律意见书（一） 致：蓝星安迪苏股份有限公司 北京市金杜律师事务所（以下简称"本所"）接受蓝星安迪苏股份有限公司（以 下简称"发行人"）委托，担任发行人向特定对象发行 A 股股票（以下简称"本次 发行"）的专项法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理办法》（以 下简称"《注册管理办法》"）、《律师事务所从事证券法律业务管理办法》（以下简 称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》 （以下简称"《证券法律业务执业规则》"）、《公开发行证券公司信息披露的编报 规则第 12 号－－公开发行证券的法律意见书和律师工作报告》等中华人民共和 国境内（以下简称"中国境内"，为本法律意见书之目的，不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、部门规 章及规范性文件和中国证券监督管理委员会（以下简称"中国证监会"）、上海证 券交易所（以下简称"上交所"）的有关规定 ...

关于蓝星安迪苏股份有限公司 向特定对象发行股票申请文件的 审核问询函回复的专项说明 上海证券交易所： 毕马威华振会计师事务所 (特殊普通合伙) (以下简称"本所"或"我们") 接受 蓝星安迪苏股份有限公司 (以下简称"公司"或"发行人") 的委托，按照中国注册会 计师审计准则(以下简称"审计准则")审计了发行人 2022 年 12 月 31 日、2023 年 12 月 31 日及 2024 年 12 月 31 日的合并及母公司资产负债表，2022 年度、2023 年度及 2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母 公司股东权益变动表以及相关财务报表附注（以下简称"财务报表"），并分别于 2023 年 3 月 30 日、2024 年 3 月 28 日及 2025 年 2 月 27 日出具了无保留意见 的审计报告（报告号分别为毕马威华振审字第 2304245 号、毕马威华振审字第 2405018 号及毕马威华振审字第 2500255 号）。我们的目标是对财务报表整体 是否不存在由于舞弊或错误导致的重大错报获取合理保证。我们审计的目的并不 是对上述财务报表中的任何个别账户或项目的余额或金额 ...

关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票申请文件的 审核问询函的回复报告 保荐人（主承销商） 上海证券交易所： 根据贵所于 2025 年 4 月 29 日出具的《关于蓝星安迪苏股份有限公司向特定 对象发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕131 号） （以下简称"审核问询函"）的要求，蓝星安迪苏股份有限公司（以下简称"安 迪苏"、"发行人"或"公司"）已会同中信证券股份有限公司（以下简称"保 荐机构"或"保荐人"）、毕马威华振会计师事务所（特殊普通合伙）（以下简 称 "申报会计师"或"毕马威"）、北京市金杜律师事务所（以下简称"发行 人律师"、"申报律师"或"金杜"）等有关中介机构，本着勤勉尽责、诚实守 信的原则，对审核问询函所列的问题进行了逐项核查和落实，现回复如下，请予 审核。 本审核问询函回复报告的字体代表以下含义： | 审核问询函所列问题 | 黑体 | | --- | --- | | 对问题的回复 | 宋体 | | 申报文件的修订、补充披露（如有） | 楷体（加粗） | 如无特别说明，本审核问询函回复报告中的简称或名词的释义与《蓝星安迪 苏股份有限公司向特定对象发 ...

关于向特定对象发行股票申请文件的审核问询函回复更新 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所（以下简称"上交所"）出具的上证上审（再融资）〔2025〕 131 号《关于蓝星安迪苏股份有限公司向特定对象发行股票申请文件的审核问询函》 （以下简称"审核问询函"）的相关要求，蓝星安迪苏股份有限公司（以下简称"公司"） 会同相关中介机构对《审核问询函》所列问题进行了认真研究和逐项落实，并对有关 问题进行了说明、论证分析和逐项回复，具体内容详见公司于 2025 年 6 月 27 日在上 交所网站（www.sse.com.cn）披露的相关公告文件。 证券代码：600299 证券简称：安迪苏 公告编号：2025-034 蓝星安迪苏股份有限公司 公司本次向特定对象发行 A 股股票事项尚需上交所审核通过，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施。最终能否通过上交所 审核，并获得中国证监会同意注册的决定及其时间尚存在不确定性。公司将根据进展 情况，严格按照上市公司向特定对象 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025- 033 特此公告。 蓝星安迪苏股份有限公司董事会 2025 年 7 月 16 日 附件：丁冰晶先生简历 蓝星安迪苏股份有限公司 关于聘任公司副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为完善蓝星安迪苏股份有限公司（以下简称"公司"）治理结构，保证公 司管理层工作的规范运作，根据《公司法》《公司章程》及相关法律法规的规 定，公司董事会提名委员会提名并审核副总经理候选人的任职资格，发表审核 意见如下：经审核丁冰晶先生的个人履历(简历后附)及资料，其具备担任公司 高级管理人员的任职资格和履职能力，不存在《公司法》《公司章程》中规定 不得担任公司高级管理人员的情形；不存在被中国证监会采取市场禁入措施， 并且禁入期限尚未届满的情形；不存在被证券交易所公开认定为不适合担任上 市公司高级管理人员，且期限未满的情形；也未曾受到中国证监会和证券交易 所的处罚或惩戒。因此，同意将聘任丁冰晶先生为公司副总经理的议案提交董 事会审议。 公司于 2025 年 7 月 1 ...

Core Insights - The baking enzyme preparation industry in China is experiencing rapid growth driven by the expanding market for baked goods and increasing consumer demand for healthy, functional products, particularly low-sugar and high-fiber options [1][14] - The market size of China's baking enzyme preparation industry is projected to reach approximately 2.15 billion yuan in 2024, with a year-on-year growth of 15%, and is expected to further grow to 2.48 billion yuan by 2025 [14] - The industry is characterized by a complete supply chain, including upstream raw material supply, midstream production, and downstream applications, with significant advancements in technology and product innovation [6][12] Industry Overview - Baking enzyme preparations are natural protein catalysts extracted through biotechnology, aimed at improving the quality, processing performance, and nutritional value of baked goods [2][3] - These enzymes enhance dough extensibility, fermentation efficiency, delay aging, and optimize texture by breaking down components such as starch, protein, or cellulose [2][3] - The main types of baking enzymes include amylases, proteases, xylanases, lipases, and glucose oxidases, sourced from microorganisms or plants, known for their efficiency and safety [2][3] Market Dynamics - The retail market for baked goods in China is expected to reach 611.07 billion yuan in 2024, growing at a rate of 8.8%, with health-oriented and scenario-based products becoming new consumer hotspots [8] - The number of baking stores in China is projected to increase from 285,000 in 2020 to 338,000 by 2025, although the annual growth rate has slowed from 5.6% to 0.6% [10] - The enzyme preparation industry is expected to produce 2.074 million tons in 2024, reflecting a year-on-year growth of 7.5%, with food industry applications maintaining a 42.3% market share [12][14] Competitive Landscape - The baking enzyme preparation industry in China is characterized by a competitive landscape where international giants dominate the high-end market, while domestic companies are rapidly catching up [18][20] - Major international brands like Novozymes and Genencor lead the high-end market, while domestic firms such as Yidoli and Blue Biological are making strides in basic enzyme products and gradually moving into high-end fields [18][20] - The market concentration is increasing, with the East China region accounting for over 60% of the market share, driven by technological advancements and economies of scale [18][20] Development Trends - The industry is evolving towards high-end technology, health sustainability, and global market integration, with innovations in biotechnology driving the development of efficient and stable enzyme preparations [23][24] - There is a growing demand for functional enzyme preparations that cater to health-conscious consumers, with a shift towards low-sensitivity and high-fiber products [24] - The domestic market is expanding, particularly in the eastern regions, while companies are also establishing production facilities in Southeast Asia to leverage local resources and reduce costs [25]

Group 1 - The company announced the resignation of Vice President Frank Chmitelin, effective from July 1, 2025, due to retirement [1][2]. - Frank Chmitelin has completed the necessary work handover according to relevant laws and company regulations, ensuring that his departure will not affect the company's normal operations and management [2][3]. - The company expressed gratitude for Frank Chmitelin's contributions to its development and compliance during his tenure as Vice President [3].

| 姓名 | 离任 职务 | 离任时间 | | 原定任期 到期日 原因 | 离任 | 是否继续在 上市公司及 其控股子公 | 具体 职务 （如 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 公开承诺 | | | | | | | | 司任职 | 适用） | | | Frank | 副总 | 年 2025 7 | 2027 | 年 退休 9 | | 否 | 不适 | 否 | | Chmitelin | 经理 | 月 日 1 | 月 | 日 18 | | | 用 | | 蓝星安迪苏股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"公司"）董事会于近日收到公司副总经 理 Frank Chmitelin 先生的书面辞职报告。 一、离任的基本情况 证券代码：600299 证券简称：安迪苏 公告编号：2025-032 二、离任对公司的影 ...

Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange regarding its application for a specific issuance of A-shares [1][2] - The company, along with relevant intermediaries, conducted a thorough study and provided detailed responses to the questions raised in the inquiry letter [1] - The issuance of A-shares is subject to approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission, with uncertainty regarding the approval timeline [2] Group 2 - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the process progresses [2]

Core Viewpoint - Blue Star Adisseo Co., Ltd. is seeking to raise funds through a specific stock issuance, with a total investment of 6.857 billion yuan for four projects and working capital, aiming for an internal rate of return between 13.57% and 25% [2][3]. Fundraising and Investment Projects - The total investment for the fundraising projects is 6.857 billion yuan, with a maximum of 3 billion yuan to be raised, allocated to four projects and 900 million yuan for working capital [2]. - The construction period for the four projects ranges from 15 to 26 months, with expected benefits from cost reductions and additional income from biogas [2]. Project Details - The first project is a solid methionine production project with an investment of approximately 493.23 million yuan, accounting for 100% of the total investment for this project [3][4]. - The second project involves a special feed additive with a total investment of 304.97 million yuan, with 60 million yuan sourced from the fundraising [11]. - The third project focuses on acrylic wastewater treatment and water reuse, with a total investment of 324.97 million yuan and 100 million yuan from the fundraising [15][19]. Cost Estimation and Reasonableness - The cost estimation for the solid methionine project is based on market prices and relevant cost estimation methods, ensuring its reasonableness [4][5]. - The unit construction cost for the solid methionine project is 3,593.25 yuan per square meter, which is within the range of similar projects in the region [7][12]. - The equipment costs for the projects are estimated based on supplier quotes and historical prices, ensuring that the pricing is reasonable [13][14]. Financial Justification - The financing scale is justified by the company's operational needs, cash flow, and projected funding gaps, with a future funding shortfall of approximately 5.566 billion yuan over the next three years [19].